Multivalent binding molecules activating wnt signaling and uses thereof

A technology that combines molecules and binding sites, and is applied in the direction of growth factors/inducing factors, medical preparations of non-active ingredients, hybrid peptides, etc., and can solve problems such as inability to use

Pending Publication Date: 2020-11-24
ANTLERA THERAPEUTICS INC
View PDF27 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The hydrophobicity and sensitive tertiary structure of Wnt proteins make their biochemical purification challenging and their use in vivo and in vitro

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Multivalent binding molecules activating wnt signaling and uses thereof
  • Multivalent binding molecules activating wnt signaling and uses thereof
  • Multivalent binding molecules activating wnt signaling and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0135] One embodiment of the present invention is a method for preparing a multivalent binding molecule that activates the Wnt signaling pathway, comprising:

[0136] a) selecting an Fc domain with a C-terminus and an N-terminus, such as that of an immunoglobulin comprising a CH3 domain, such as IgG, such as IgG1,

[0137] b) recognize antibodies with binding specificity for more than one FZD receptor and

[0138] c) recognizes an antibody with binding specificity to a Wnt co-receptor;

[0139] d) producing a nucleic acid molecule comprising

[0140] (i) a nucleotide sequence encoding the selected Fc domain,

[0141] (ii) a nucleotide sequence encoding the VL and / or VH of the antibody derived from step b, and

[0142] (iii) a nucleotide sequence encoding the VL and / or VH of the antibody derived from step c,

[0143]d) expressing the nucleic acid molecule of (d) to produce a polypeptide that forms a multivalent binding molecule through dimerization of the Fc domain, the mul...

Embodiment I

[0176] 1. Development of multivalent FZD agonists

[0177] To prepare multivalent binding molecules with a first binding domain comprising a FZD diabody and a second binding domain comprising a co-receptor diabody, we selected the enriched half of the FZD receptor by using conventional phage display technology. Those bound by the cystine domain (CRD), FZD-specific antibodies were identified from a synthetic Fab phage library (Library F; see US Pub. No. 2016 / 0194394, inventor Sidhu et al.). Affinity or specific maturation is performed as desired. For example, pan-FZD binding antibody #5019 (recognizing FZD1, 2, 4, 5, 7 and 8) was matured from an FZD7-derived antibody using the FZD4 CRD as antigen. Our previous work also identified several antibodies fully specific to FZD4 (5038, 5044, 5048, 5062, 5063, 5080, 5081) or to FZD5 (2928) (see, for example, US20160194394, inventor Sidhu et al. and WO2017127933A1 , inventor Pan et al).

[0178] These FZD antibodies are used to prepa...

Embodiment II

[0217] Example II - Synthetic Antibodies Targeting FZD and LRP6

[0218] We previously applied phage display to generate hundreds of synthetic antibodies using nine recombinant FZD CRDs as antigens (the FZD3 CRD could not be purified) (Steinhart et al. Nat. Med. 23, 60 (2016); Pavlovic et al. MAbs (2018), doi: 10.1080 / 19420862.2018.1515565). System characterization revealed a continuous spectrum of specificity, with some Abs exhibiting broad specificity, such as the pan-FZD Ab (FP) recognizing FZD1 / 2 / 4 / 5 / 7 / 8 ( Figure 11A ), other Abs showed more restricted specificity, and some were monospecific ( Figure 11B ). Functional characterization revealed that some antibodies competed with Wnt and inhibited β-catenin signaling, while others were noncompetitive and did not interfere with Wnt signaling ( Figure 11B ). Altogether, we fully characterized 161 anti-FZD antibodies, including 47 Wnt signaling inhibitors. Unexpectedly, as discussed herein, regardless of whether they co...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Described herein are methods to affect binding by a multivalent binding molecule to a FZD receptor and a Wnt co-receptor on a cell wherein binding by the multivalent binding molecule to both FZD receptor and co-receptor on the cell activates a Wnt signaling pathway. Also described herein are multivalent binding molecules comprising a FZD receptor binding domain and a Wnt co-receptor biding domainon either end of an Fc domain that activate a Wnt signaling pathway and methods for their use.

Description

[0001] This application claims the benefit under 35 U.S.C. 119(e) of U.S. Provisional Application No. 62 / 630,772, filed February 14, 2018, the entire contents of which are incorporated herein by reference. [0002] This application contains a Sequence Listing, which has been electronically filed in ASCII format, and is hereby incorporated by reference in its entirety. Said ASCII copy was created on February 12, 2019, named 115773_PA895WO_SL.txt, and was 220,360 bytes in size. Background technique [0003] The Wnt signaling pathway is critical for embryonic development and tissue homeostasis in adults. Wnt ligands are secreted growth factors that regulate various cellular processes such as proliferation, differentiation, survival and migration. Wnt ligands are universally important for controlling tissue stem cell self-renewal and regulating many progenitor cell populations. The hydrophobicity and sensitive tertiary structure of Wnt proteins make their biochemical purificatio...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K19/00A61K39/395A61K47/68C07K14/705C07K16/00C07K16/28C12N5/071
CPCC07K14/71C07K14/475C07K16/28C07K2317/626C07K16/2863C07K2317/31C07K2317/75C07K2317/55C07K2319/00C07K2317/52C07K2317/35A61K2039/505C07K2319/30C07K2319/75A61P19/08C07K16/22C07K2317/622
Inventor S·安格斯S·西杜陶余勇
Owner ANTLERA THERAPEUTICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap